Possibilities of therapy for neuropathic pain caused by chemo-induced polyneuropathy

Cover Page

Cite item

Full Text

Abstract

Background. In oncological practice, the study of neuropathic pain syndrome (NPS) in patients receiving chemotherapy (CT) is relevant. This disorder is accompanied by significant motor and autonomic disorders in the upper and lower extremities, which negatively affects the quality of life and daily activity of patients.

Aim. To study the formation and evaluation of the effectiveness of NPS therapy in cancer patients with chemo-induced polyneuropathy (CIPN) at various stages of CT.

Materials and methods. Sixty three oncological patients with different localization and stage of malignant neoplasm, having NPS and undergoing CT were examined. The average age was 56.3±9.4 years. Most often, patients had cancer of the stomach, breast, and ovaries. The main neurotoxic drugs used in the treatment of the tumor process were oxaliplatin, docetaxel, paclitaxel. The combination therapy was dominated by the carboplatin + paclitaxel scheme. As a therapy for NPS, 31 patients were prescribed a drug with antioxidant activity of azoximer bromide; 32 patients were prescribed duloxetine. The control group included 30 patients with cancer and CIPN who did not receive concomitant symptomatic therapy.

Results. During the use of symptomatic therapy, a decrease in the severity of NPS was observed in all patients in the main groups compared with the control group. There was a significant decrease in sensitive disorders, especially in the duloxetine group. In the group of patients receiving azoximer bromide, it was also possible to stabilize the pathological process in the reflex sphere.

Conclusion. CIPN and the associated NPS is an iatrogenic complication in cancer patients undergoing CT. Polyneuropathy not only significantly worsens the quality of life of patients, but also leads to a decrease in the effectiveness of treatment due to the need to correct therapeutic regimens. Therefore, early detection, proper monitoring and competent management of CIPN are important aspects of cancer patient care aimed at improving therapy outcomes and the overall well-being of patients.

About the authors

Svetlana V. Chubykina

Pirogov Russian National Research Medical University

Author for correspondence.
Email: svetasveta@bk.ru
ORCID iD: 0000-0001-5196-8992

Graduate Student

Russian Federation, Moscow

Marina Yu. Tatarinova

Pirogov Russian National Research Medical University

Email: nevrolog.marinay@gmail.com
ORCID iD: 0000-0002-2701-7326

D. Sci. (Med.), Assoc. Prof.

Russian Federation, Moscow

Georgy G. Avakyan

Pirogov Russian National Research Medical University

Email: avakyan_georgy@mail.ru
ORCID iD: 0000-0002-8985-8227

D. Sci. (Med.)

Russian Federation, Moscow

Rostislav I. Knyazev

Blokhin National Medical Research Center of Oncology; Russian Medical Academy of Continuous Professional Education

Email: sluwba@mail.ru
ORCID iD: 0000-0002-6341-0897

Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

References

  1. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204-5. doi: 10.1016/j.pain.2011.06.017
  2. Давыдов О.С., Яхно Н.Н., Кукушкин М.Л., и др. Невропатическая боль: клинические рекомендации по диагностике и лечению Российского общества по изучению боли. Российский журнал боли. 2018;4(58):5-41 [Davydov OS, Yakhno NN, Kukushkin ML, et al. Neuropathic pain: clinical guidelines on the diagnostics and treatment from the Russian Association for the Studying of Pain. Rossiiskii Zhurnal Boli. 2018;4(58):5-41 (in Russian)]. doi: 10.25731/RASP.2018.04.025
  3. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;16(3):17002. doi: 10.1038/nrdp. 2017.2
  4. Yamamota S, Egashira N. Drug Repositioning for the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Mechanism- and Screening-Based Strategy. Front Pharmacol. 2021;14(11):607780. doi: 10.3389/fphar.2020.607780
  5. Kinga S. Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy. Pharmacol Rep. 2020;72(3):486-507. doi: 10.1007/s43440-020-00109-y
  6. Холодова Н.Б., Понкратова Ю.А., Синкин М.В. Клинические и электронейромиографические особенности постхимиотерапевтической полинейропатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(9):59-66 [Kholodova NB, Ponkratova IuA, Sinkin MV. Clinical and electromyography characteristics of chemotherapy-induced polyneuropathy. Zhurnal Nevrologii i Psikhiatrii im. SS Korsakova. 2017;117(9):59-66 (in Russian)]. doi: 10.17116/jnevro20171179159-66
  7. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-70. doi: 10.1016/j.pain.2014.09.020
  8. Brouwers EE, Huitema AD, Boogerd W, et al. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncologica. 2009;48:832-41. doi: 10.1080/02841860902806609
  9. Pietrangeli A, Leandri M, Terzoli E, et al. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol. 2006;56(1):13-6. doi: 10.1159/000094376
  10. Vilholm OJ, Christensen AA, Zedan AH, et al. Drug-Induced Peripheral Neuropathy. Basic Clin Pharmacol Toxicol. 2014;115(2):185-92. doi: 10.1111/bcpt.12261
  11. Argyriou A, Bruna J, Marmiroli P, et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol. 2012;82(1):51-77. doi: 10.1016/j.critrevonc.2011.04.012
  12. Hoffmeyer S, Burk O, von Richter O, Arnold HP. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. PNAS. 2000;97(7):3473-8. doi: 10.1073/pnas.97.7.3473
  13. Hershman DL, Lacchetti C, Dworkin RH, et al. American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941-67. doi: 10.1200/JCO.2013.54.0914
  14. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325-48. doi: 10.1200/JCO.20.01399
  15. Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;12(1):90-2. doi: 10.1016/j.ad.2019.05.009
  16. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Publish Date: November 27, 2017 Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed: 22.03.2024.
  17. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health.1990;13(4):227-36. doi: 10.1002/nur.4770130405
  18. Bouhassira D, Attal N, Alchaar N, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1):29-36. doi: 10.1016/j.pain.2004.12.010
  19. Freynhagen R, Baron R, Gockel U. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911-20. doi: 10.1185/030079906X132488
  20. Ватутин Н.Т., Склянная Е.В., Эль-Хатиб М.А., и др. Периферические полинейропатии, индуцированные различными химиотерапевтическими агентами: современное состояние проблемы. Гематология и трансфузиология. 2016;61(2):105-9 [Vatutin MT, Sklyannaya EV, El-Khatib MA, et al. Peripheral neurophathies induced by various chemotherapeutic agents: current state of the problem. Hematology and Transfusiology. 2016;61(2):105-9 (in Russian)]. doi: 10.18821/0234-5730-2016-61-2-105-109
  21. Zajączkowska R, Kocot-Kępska M, Leppert W, et al. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. doi: 10.3390/ijms20061451
  22. Семенова А.И. Кардио- и нейротоксичность противоопухолевых препаратов (патогенез, клиника, профилактика, лечение). Практическая онкология. 2009;10(3):168-76 [Semenova AI. Cardio- and neurotoxicity of anticancer drugs (pathogenesis, clinic, prevention, treatment). Practical Oncology. 2009;10(3):168-76 (in Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Frequency of sensory disturbances.

Download (126KB)
Indexing metadata

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies